The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing

Adam C. Berger, Andrew L. Feldman, Michael F X Gnant, Erwin A. Kruger, B. Kim Lee Sim, Stephen Hewitt, William D. Figg, H. Richard Alexander, Steven K. Libutti

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Background. Endostatin is a potent angiogenesis inhibitor, which is currently being used in Phase I trials as an antitumor agent. The purpose of this study was to determine whether endostatin has an effect on wound healing in a murine model. Materials and methods. The function of endostatin was confirmed using a human microvascular endothelial cell (HMVEC) proliferation assay in which cells are treated for 4 days with growth media plus or minus endostatin. Full-thickness incisions were made on the dorsum of athymic nude mice and closed primarily with skin staples. PVA sponges were implanted in some wounds to determine vascular ingrowth. Subsequently, mice were treated with recombinant human endostatin at 20 mg/kg/day or 50 mg/kg/dose BID versus control for a total of 14 days. On Days 2, 4, 8, 12, and 16, three mice per group had serum samples drawn and were sacrificed. Perpendicular breaking strength (N) was determined using an Instron 5540 tensometer. Wound strength was determined by dividing breaking strength by wound area (N/cm2). Vascular density in sponges was determined using CD31 immunohistochemistry. Serum endostatin concentrations were determined using a commercially available ELISA kit. Results. Endostatin caused a significant reduction of endothelial cell proliferation after 4 days compared to media alone (72%, P = 0.031). At all time points tested, there was no statistical difference in the wound- breaking strength between endostatin and control-treated mice at either the low or high dose. Serum endostatin levels were consistently 10-fold higher in endostatin-treated mice than in controls. No differences in vascular density were seen in endostatin versus control-treated mice as determined by CD31 immunohistochemistry of PVA sponges. Conclusion. Therapy with human endostatin does not induce a significant decrease in breaking strength of cutaneous wounds in mice.

Original languageEnglish (US)
Pages (from-to)26-31
Number of pages6
JournalJournal of Surgical Research
Volume91
Issue number1
DOIs
StatePublished - Jun 1 2000
Externally publishedYes

Fingerprint

Endostatins
Angiogenesis Inhibitors
Wound Healing
Skin
Porifera
Wounds and Injuries
Blood Vessels
Nude Mice
Endothelial Cells
Serum
Immunohistochemistry
Cell Proliferation
Antineoplastic Agents

Keywords

  • Angiogenesis
  • Endostatin
  • Endothelial cells
  • Tensile strength

ASJC Scopus subject areas

  • Surgery

Cite this

Berger, A. C., Feldman, A. L., Gnant, M. F. X., Kruger, E. A., Sim, B. K. L., Hewitt, S., ... Libutti, S. K. (2000). The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. Journal of Surgical Research, 91(1), 26-31. https://doi.org/10.1006/jsre.2000.5890

The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. / Berger, Adam C.; Feldman, Andrew L.; Gnant, Michael F X; Kruger, Erwin A.; Sim, B. Kim Lee; Hewitt, Stephen; Figg, William D.; Alexander, H. Richard; Libutti, Steven K.

In: Journal of Surgical Research, Vol. 91, No. 1, 01.06.2000, p. 26-31.

Research output: Contribution to journalArticle

Berger, AC, Feldman, AL, Gnant, MFX, Kruger, EA, Sim, BKL, Hewitt, S, Figg, WD, Alexander, HR & Libutti, SK 2000, 'The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing', Journal of Surgical Research, vol. 91, no. 1, pp. 26-31. https://doi.org/10.1006/jsre.2000.5890
Berger, Adam C. ; Feldman, Andrew L. ; Gnant, Michael F X ; Kruger, Erwin A. ; Sim, B. Kim Lee ; Hewitt, Stephen ; Figg, William D. ; Alexander, H. Richard ; Libutti, Steven K. / The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. In: Journal of Surgical Research. 2000 ; Vol. 91, No. 1. pp. 26-31.
@article{eba718ab69b247529733ac5c8338a0e0,
title = "The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing",
abstract = "Background. Endostatin is a potent angiogenesis inhibitor, which is currently being used in Phase I trials as an antitumor agent. The purpose of this study was to determine whether endostatin has an effect on wound healing in a murine model. Materials and methods. The function of endostatin was confirmed using a human microvascular endothelial cell (HMVEC) proliferation assay in which cells are treated for 4 days with growth media plus or minus endostatin. Full-thickness incisions were made on the dorsum of athymic nude mice and closed primarily with skin staples. PVA sponges were implanted in some wounds to determine vascular ingrowth. Subsequently, mice were treated with recombinant human endostatin at 20 mg/kg/day or 50 mg/kg/dose BID versus control for a total of 14 days. On Days 2, 4, 8, 12, and 16, three mice per group had serum samples drawn and were sacrificed. Perpendicular breaking strength (N) was determined using an Instron 5540 tensometer. Wound strength was determined by dividing breaking strength by wound area (N/cm2). Vascular density in sponges was determined using CD31 immunohistochemistry. Serum endostatin concentrations were determined using a commercially available ELISA kit. Results. Endostatin caused a significant reduction of endothelial cell proliferation after 4 days compared to media alone (72{\%}, P = 0.031). At all time points tested, there was no statistical difference in the wound- breaking strength between endostatin and control-treated mice at either the low or high dose. Serum endostatin levels were consistently 10-fold higher in endostatin-treated mice than in controls. No differences in vascular density were seen in endostatin versus control-treated mice as determined by CD31 immunohistochemistry of PVA sponges. Conclusion. Therapy with human endostatin does not induce a significant decrease in breaking strength of cutaneous wounds in mice.",
keywords = "Angiogenesis, Endostatin, Endothelial cells, Tensile strength",
author = "Berger, {Adam C.} and Feldman, {Andrew L.} and Gnant, {Michael F X} and Kruger, {Erwin A.} and Sim, {B. Kim Lee} and Stephen Hewitt and Figg, {William D.} and Alexander, {H. Richard} and Libutti, {Steven K.}",
year = "2000",
month = "6",
day = "1",
doi = "10.1006/jsre.2000.5890",
language = "English (US)",
volume = "91",
pages = "26--31",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing

AU - Berger, Adam C.

AU - Feldman, Andrew L.

AU - Gnant, Michael F X

AU - Kruger, Erwin A.

AU - Sim, B. Kim Lee

AU - Hewitt, Stephen

AU - Figg, William D.

AU - Alexander, H. Richard

AU - Libutti, Steven K.

PY - 2000/6/1

Y1 - 2000/6/1

N2 - Background. Endostatin is a potent angiogenesis inhibitor, which is currently being used in Phase I trials as an antitumor agent. The purpose of this study was to determine whether endostatin has an effect on wound healing in a murine model. Materials and methods. The function of endostatin was confirmed using a human microvascular endothelial cell (HMVEC) proliferation assay in which cells are treated for 4 days with growth media plus or minus endostatin. Full-thickness incisions were made on the dorsum of athymic nude mice and closed primarily with skin staples. PVA sponges were implanted in some wounds to determine vascular ingrowth. Subsequently, mice were treated with recombinant human endostatin at 20 mg/kg/day or 50 mg/kg/dose BID versus control for a total of 14 days. On Days 2, 4, 8, 12, and 16, three mice per group had serum samples drawn and were sacrificed. Perpendicular breaking strength (N) was determined using an Instron 5540 tensometer. Wound strength was determined by dividing breaking strength by wound area (N/cm2). Vascular density in sponges was determined using CD31 immunohistochemistry. Serum endostatin concentrations were determined using a commercially available ELISA kit. Results. Endostatin caused a significant reduction of endothelial cell proliferation after 4 days compared to media alone (72%, P = 0.031). At all time points tested, there was no statistical difference in the wound- breaking strength between endostatin and control-treated mice at either the low or high dose. Serum endostatin levels were consistently 10-fold higher in endostatin-treated mice than in controls. No differences in vascular density were seen in endostatin versus control-treated mice as determined by CD31 immunohistochemistry of PVA sponges. Conclusion. Therapy with human endostatin does not induce a significant decrease in breaking strength of cutaneous wounds in mice.

AB - Background. Endostatin is a potent angiogenesis inhibitor, which is currently being used in Phase I trials as an antitumor agent. The purpose of this study was to determine whether endostatin has an effect on wound healing in a murine model. Materials and methods. The function of endostatin was confirmed using a human microvascular endothelial cell (HMVEC) proliferation assay in which cells are treated for 4 days with growth media plus or minus endostatin. Full-thickness incisions were made on the dorsum of athymic nude mice and closed primarily with skin staples. PVA sponges were implanted in some wounds to determine vascular ingrowth. Subsequently, mice were treated with recombinant human endostatin at 20 mg/kg/day or 50 mg/kg/dose BID versus control for a total of 14 days. On Days 2, 4, 8, 12, and 16, three mice per group had serum samples drawn and were sacrificed. Perpendicular breaking strength (N) was determined using an Instron 5540 tensometer. Wound strength was determined by dividing breaking strength by wound area (N/cm2). Vascular density in sponges was determined using CD31 immunohistochemistry. Serum endostatin concentrations were determined using a commercially available ELISA kit. Results. Endostatin caused a significant reduction of endothelial cell proliferation after 4 days compared to media alone (72%, P = 0.031). At all time points tested, there was no statistical difference in the wound- breaking strength between endostatin and control-treated mice at either the low or high dose. Serum endostatin levels were consistently 10-fold higher in endostatin-treated mice than in controls. No differences in vascular density were seen in endostatin versus control-treated mice as determined by CD31 immunohistochemistry of PVA sponges. Conclusion. Therapy with human endostatin does not induce a significant decrease in breaking strength of cutaneous wounds in mice.

KW - Angiogenesis

KW - Endostatin

KW - Endothelial cells

KW - Tensile strength

UR - http://www.scopus.com/inward/record.url?scp=0034212417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034212417&partnerID=8YFLogxK

U2 - 10.1006/jsre.2000.5890

DO - 10.1006/jsre.2000.5890

M3 - Article

C2 - 10816345

AN - SCOPUS:0034212417

VL - 91

SP - 26

EP - 31

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -